公开(公告)号：US20180037623A1

公开(公告)日：2018-02-08

申请号：US15532634

申请日：2015-12-02

Applicant: Novartis AG

Inventor： Donglin GUO ,  Chikwendu IBEBUNJO

IPC: C07K14/50 ,  C12N15/62 ,  C12N9/24

CPC classification number: C07K14/50 ,  A61K38/00 ,  C07K2319/00 ,  C07K2319/30 ,  C12N9/2402 ,  C12N15/62 ,  C12Y302/01031

Abstract: The present disclosure is directed to compositions and methods related to an alpha sKlotho variant or fragment, in which 1 to up to about 20 amino acids have been deleted from the C-terminus, optionally also having mutations at V563 and/or K795. The present disclosure also pertains to an alpha sKlotho polypeptide variant or fragment, having mutations at V563 and/or K795, wherein the polypeptide variant or fragment is full-length, or optionally 1 to up to about 20 amino acids have been deleted from the C-terminus. The present disclosure also pertains to fusion polypeptides comprising: (a) an alpha sKlotho, in which 1 to up to about 20 amino acids have been deleted from the C-terminus, optionally also having mutations at V563 and/or K795; (b) a linker; and (c) FGF23, optionally having a mutation at R179, C206 and/or C244, or (c) serum albumin.